Literature DB >> 8807077

In vitro activities in new oxazolidinone antimicrobial agents against enterococci.

G M Eliopoulos1, C B Wennersten, H S Gold, R C Moellering.   

Abstract

The comparative in vitro activities of two new oxazolidinone antimicrobial agents, U-100592 and U-100766, against 180 isolates of enterococci representing several resistance profiles were examined by using an agar dilution technique. The two oxazolidinones inhibited all isolates, including strains resistant to vancomycin, ampicillin, and minocycline, at concentrations between 1 and 4 micrograms/ml.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8807077      PMCID： PMC163410     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Identification of Enterococcus species isolated from human infections by a conventional test scheme.

Authors:  R R Facklam; M D Collins
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

Review 2.  Emergence of Enterococcus as a significant pathogen.

Authors:  R C Moellering
Journal:  Clin Infect Dis       Date:  1992-06       Impact factor: 9.079

3.  Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound.

Authors:  J S Daly; G M Eliopoulos; S Willey; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

4.  In vitro activities of two glycylcyclines against gram-positive bacteria.

Authors:  G M Eliopoulos; C B Wennersten; G Cole; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 5.  Genetics and mechanisms of glycopeptide resistance in enterococci.

Authors:  M Arthur; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

6.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

7.  A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci.

Authors:  H S Gold; S Unal; E Cercenado; C Thauvin-Eliopoulos; G M Eliopoulos; C B Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

8.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

9.  Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.

Authors:  J S Daly; G M Eliopoulos; E Reiszner; R C Moellering
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

10.  Vancomycin resistance is encoded on a pheromone response plasmid in Enterococcus faecium 228.

Authors:  S Handwerger; M J Pucci; A Kolokathis
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191
  10 in total
  19 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Increasing Antimicrobial Resistance: Therapeutic Implications for Enterococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

3.  In vitro activity of the new oxazolidinone AZD2563 against Enterococci.

Authors:  G M Eliopoulos; C B Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 4.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

Review 5.  Linezolid: a review of its use in the management of serious gram-positive infections.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient.

Authors:  Fabio Arena; Tommaso Giani; Angelo Galano; Marcello Pasculli; Valeria Peccianti; Maria Iris Cassetta; Andrea Novelli; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2013-12       Impact factor: 5.191

7.  Antibacterial agents that inhibit two-component signal transduction systems.

Authors:  J F Barrett; R M Goldschmidt; L E Lawrence; B Foleno; R Chen; J P Demers; S Johnson; R Kanojia; J Fernandez; J Bernstein; L Licata; A Donetz; S Huang; D J Hlasta; M J Macielag; K Ohemeng; R Frechette; M B Frosco; D H Klaubert; J M Whiteley; L Wang; J A Hoch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

8.  Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.

Authors:  Vandana Kalia; Rajni Miglani; Kedar P Purnapatre; Tarun Mathur; Smita Singhal; Seema Khan; Sreedhara R Voleti; Dilip J Upadhyay; Kulvinder Singh Saini; Ashok Rattan; V Samuel Raj
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

9.  Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates.

Authors:  E-M Klupp; A Both; C Belmar Campos; H Büttner; C König; M Christopeit; M Christner; M Aepfelbacher; H Rohde
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-15       Impact factor: 3.267

10.  A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?

Authors:  G G Zhanel; C Shroeder; L Vercaigne; A S Gin; J Embil; D J Hoban
Journal:  Can J Infect Dis       Date:  2001-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.